Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, 7180 Highland Drive (151C-H), Pittsburgh, PA 15206, USA.
J Addict Med. 2012 Sep;6(3):233-9. doi: 10.1097/ADM.0b013e31825f491b.
To explore attitudes toward hepatitis C antiviral therapy in a real-world setting, we asked patients in opioid agonist treatment who were offered antiviral therapy about perceived barriers to initiating therapy.
We recruited patients in opioid agonist treatment who had previously been offered cost-free hepatitis C antiviral therapy in a clinical trial. We collected demographic and open-ended interview data. The semistructured interview guide included questions about attitudes toward hepatitis C therapy and barriers to initiating treatment. Each interview was audio recorded and transcribed verbatim. We used the qualitative editing method to analyze the interview transcripts.
We enrolled 19 patients who had been approached to initiate hepatitis C therapy in a clinical trial. All participants were low-income men, with one third self-identifying as racial minorities. When asked about possible barriers to treatment, multiple problems emerged, including the fear of treatment side effects, difficulties with health care providers, limited access to medical care and health information, and misperceptions about antiviral therapy.
Despite intense educational efforts, concerns over antiviral therapy, relations with providers, and access to the health care system remain critical barriers. These factors should be addressed to improve antiviral therapy rates for patients receiving opioid agonist treatment.
为了在真实环境中探索丙型肝炎抗病毒治疗的态度，我们询问了在一项临床试验中被提供免费丙型肝炎抗病毒治疗的阿片类药物成瘾治疗患者，了解他们对开始治疗的障碍的看法。
我们招募了在阿片类药物成瘾治疗中曾被提供免费丙型肝炎抗病毒治疗的患者。我们收集了人口统计学和开放式访谈数据。半结构化访谈指南包括对丙型肝炎治疗态度和开始治疗障碍的问题。每次访谈都进行录音，并逐字记录。我们使用定性编辑方法来分析访谈记录。
我们招募了 19 名在临床试验中被邀请开始丙型肝炎治疗的患者。所有参与者都是低收入男性，三分之一的人自认为是少数族裔。当被问及可能的治疗障碍时，出现了多种问题，包括对治疗副作用的恐惧、与医疗服务提供者的困难、获得医疗保健和健康信息的有限性，以及对抗病毒治疗的误解。
尽管进行了密集的教育努力，但对抗病毒治疗、与提供者的关系以及获得医疗保健系统的关注仍然是关键障碍。这些因素应加以解决，以提高接受阿片类药物成瘾治疗患者的抗病毒治疗率。
